Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The rabies virus envelope glycoprotein, commonly referred to as the G protein or RABV-G, is the only surface-exposed protein on the rabies virion. It plays a central role in viral entry into host cells by mediating attachment and fusion with host membranes. It is the primary target for neutralizing antibodies generated by vaccination or infection, making it a key antigen in rabies vaccines. RABV-G interacts with multiple cellular receptors, including nAChR, NCAM, and p75NTR. Conformational changes induced by acidic pH trigger fusion between viral and cellular membranes, allowing genome entry into host cells.
Neutralization of viral entry by antibodies targeting conformational epitopes; vaccines induce neutralizing antibody production
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rabies Virus Envelope Glycoprotein (RABV-G).